In Vivo Gastroprotective Effect along with Pharmacokinetics, Tissue Distribution and Metabolism of Isoliquiritigenin in Mice

Abstract

As numerous herbal products have been used as dietary supplements or functional foods, the demands of the pharmacokinetic and pharmacodynamic characteristics of active compounds are increasing in order to secure a consistent outcome (i.e., efficiency and safety). In this study, the pharmacokinetics including tissue distribution, metabolism, and protein binding of isoliquiritigenin, a chalcone found in Glycyrrhiza glabra, and its metabolite, liquiritigenin, at various doses in mice are reported. Also, correlations between the preferential tissue distribution and pharmacological effect of isoliquiritigenin in certain organs were investigated using the in vivo gastroprotective effect of isoliquiritigenin in mice with indomethacin-induced ulcer. The absorbed fraction of isoliquiritigenin was high, but the absolute bioavailability was low mainly due to its metabolism. In spite of the low bioavailability, the gastroprotective effect of isoliquiritigenin was attributed to its high distribution in the stomach. Isoliquiritigenin prevented the occurrence of gastric ulcers by indomethacin, which is associated with increased gastric mucous secretion because the pretreatment with isoliquiritigenin presumably counteracted the decreased cyclooxygenase 2 by indomethacin. This may suggest that the pharmacokinetic properties of isoliquiritigenin are useful to predict its efficacy as a gastroprotective agent in a target organ such as the stomach.

Key words

Glycyrrhiza glabra - Fabaceae - isoliquiritigenin - mice - pharmacokinetics - tissue distribution - gastroprotective effect

• References

• 1 Schmeda-Hirschmann G, Yesilada E. Traditional medicine and gastroprotective crude drugs. J Ethnopharmacol 2005; 100: 61-66
• 2 Zhou L, Liu L, Liu X, Chen P, Liu L, Zhang Y, Wu Y, Pettigrew JC, Cheng D, Yi D. Systematic review and meta-analysis of the clinical efficacy and adverse effects of Chinese herbal decoction for the treatment of gout. PLoS One 2014; 9: e85008
• 3 De Smet PA, Brauwers JR. Pharmacokinetic evaluation of herbal remedies: basic introduction, applicability, current status and regulatory needs. Clin Pharmacokinet 1997; 32: 427-436
• 4 Esimone CO, Nwafor SV, Okoli CO. In vivo evaluation of interaction between aqueous seed extract of Garcinia kola Heckel and ciprofloxacin hydrochloride. Am J Ther 2002; 9: 275-280
• 5 Singh SS. Preclinical pharmacokinetics: an approach towards safety and efficacious drugs. Curr Drug Metab 2006; 7: 165-182
• 6 Alissa EM. Medicinal herbs and therapeutic drugs interactions. Ther Drug Monit 2014; 36: 413-422
• 7 Chin YW, Jung HA, Liu Y, Su BN, Castoro JA, Keller WJ, Pereira MA, Kinghorn AD. Anti-oxidant constituents of the roots and stolons of licorice (Glycyrrhiza glabra). J Agric Food Chem 2007; 5: 4691-4697
• 8 Haraguchi H, Ishikawa H, Mizutani K, Tamura Y, Kinoshita T. Antioxidative and superoxide scavenging activities of retrochalcones in Glycyrrhiza inflata . Bioorg Med Chem 1998; 6: 339-347
• 9 Kim JY, Park SJ, Yun KJ, Cho YW, Park HJ, Lee KT. Isoliquiritigenin isolated from the roots of Glycyrrhiza uralensis inhibits LPS-induced iNOS and COX-2 expression via the attenuation of NF-kappaB in RAW 264.7 macrophages. Eur J Pharmacol 2008; 584: 175-184
• 10 Tamir S, Eizenberg M, Somjen D, Izrael S, Vaya J. Estrogen-like activity of glabrene and other constituents isolated from licorice root. J Steroid Biochem Mol Biol 2001; 78: 291-298
• 11 Baba M, Asano R, Takigami I, Takahashi T, Ohmura M, Okada Y, Sugimoto H, Arika T, Nishino H, Okuyama T. Studies on cancer chemoprevention by traditional folk medicines XXV. Inhibitory effect of isoliquiritigenin on azoxymethane-induced murine colon aberrant crypt focus formation and carcinogenesis. Biol Pharm Bull 2002; 25: 247-250
• 12 Lee CK, Son SH, Park KK, Park JH, Lim SS, Chung WY. Isoliquiritigenin inhibits tumor growth and protects the kidney and liver against chemotherapy-induced toxicity in a mouse xenograft model of colon carcinoma. J Pharmacol Sci 2008; 106: 444-451
• 13 Han SY, Chin YW, Choi YH. A new approach for pharmacokinetic studies of natural products: measurement of isoliquiritigenin levels in mice plasma, urine and feces using modified automated dosing/blood sampling system. Biomed Chromatogr 2013; 27: 741-749
• 14 Han SY, Chin YW, Kim DY, Choi YH. Simultaneous determination of α- and γ-mangostins in mouse plasma by HPLC-MS/MS method: application to a pharmacokinetic study of mangosteen extract in mouse. Chromatographia 2013; 76: 643-650
• 15 Malaney P, Nicosia SV, Dave V. One mouse, one patient paradigm: new avatars of personalized cancer therapy. Cancer Lett 2014; 344: 1-12
• 16 Viana AF, Fernandes HB, Silva FV, Oliveira IS, Freitas FF, Machado FD, Costa CL, Arcanjo DD, Chaves MH, Oliveira FA, Olivieira RC. Gastroprotective activity of Cenostigma macrophyllum Tul. var. acuminate Teles Freire leaves on experimental ulcer models. J Ethnopharmacol 2013; 150: 316-323
• 17 Davis B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093-1095
• 18 Lee YK, Chin YW, Bae JK, Seo JS, Choi YH. Pharmacokinetics of isoliquiritigenin and its metabolites in rats: low bioavailability is primarily due to the hepatic and intestinal metabolism. Planta Med 2013; 79: 1656-1665
• 19 Guo J, Liu A, Cao H, Luo Y, Pezzuto JM, Van Breemen RB. Biotransformation of the chemopreventive agent 2′,4′,4-trihydroxychalcone (isoliquiritigenin) by UDP-glucuronosyltransferases. Drug Metab Dispos 2008; 36: 2104-2112
• 20 Guo J, Liu D, Nikolic D, Zhu D, Pezzuto JM, Van Breemen RB. In vitro metabolism of isoliquiritigenin by human liver microsomes. Drug Metab Dispos 2008; 36: 461-468
• 21 Tan G, Lou Z, Dong X, Li W, Liao W, Zhu Z, Chai Y. Urinary metabolites of isoliquiritigenin in Wistar rats using UHPLC-TOF-MS-based xenometabolomics. Chromatographia 2011; 74: 341-348
• 22 Mitruka BM, Rawnsley HM. Clinical biochemical and hematological reference values in normal experimental animals and normal humans. 2nd. edition. New York: Masson Pub; 1987: 113
• 23 Lee MG, Chiou WL. Evaluation of potential causes for the incomplete bioavailability of furosemide: gastric first-pass metabolism. J Pharmacokinet Biopharm 1983; 11: 623-640
• 24 Takeuchi T, Shiratori K, Watanabe S, Chang JH, Moriyoshi Y, Shimizu K. Secretin as a potential mediator of antiulcer actions of mucosal protective agents. J Clin Gastroenterol 1991; 13 (Suppl. 01) S83-S87
• 25 Halter F, Tarnawski AS, Schmassmann A, Peskar BM. Cyclooxygenase 2-implications on maintenance of gastric mucosal integrity and ulcer healing: controversial issues and perspective. Gut 2001; 49: 443-453
• 26 Kishimoto Y, Wada K, Nakamoto K, Kawasaki H, Hasegawa J. Levels of cyclooxygenase-1 and 2 mRNA expression at various stages of acute gastric injury induced by ischemia-perfusion in rats. Arch Biochem Biophys 1998; 352: 153-157
• 27 Mayne GC, Watson DO, Hussey DJ. COX-2 mRNA is increased in oesophageal mucosal cells by a proton pump inhibitor. ANZ J Surg 2012; 82: 691-696
• 28 Choi YH, Lee U, Lee BK, Lee MG. Pharmacokinetic interaction between itraconazole and metformin in rats: competitive inhibition of metabolism of each drug by each other via hepatic and intestinal CYP3A1/2. Br J Pharmacol 2010; 161: 815-829
• 29 Gibaldi M, Perrier D. Pharmacokineics. 2nd. edition. New York: Marcel-Dekker; 1982
• 30 Choi SM, Shin JH, Kang KK, Ahn BO, Yoo M. Gastroprotective effects of DA-6034, a new flavonoid derivative, in various gastric mucosal damage models. Dig Dis Sci 2007; 52: 3075-3080
• 31 Ribeiro AR, Diniz PB, Estevam CS, Pinheiro MS, Albuquerque-Jumior RL, Thomazzi SM. Gastroprotective activity of the ethanol extract from the inner bark Caesalpinia pyramidalis in rats. J Ethnopharmacol 2013; 147: 383-388
• 32 Sun XB, Matsumoto T, Yamada H. Effects of polysaccharide fraction from the roos of Bupleurum falcatum L. on experimental gastric ulcer models in rats and mice. J Pharm Pharmacol 1991; 43: 699-704
• 33 Kitagawa H, Takeda F, Kohei H. A simple method for estimation of gastric mucus and effects of antiulcerogenic agents on the decrease in mucus during water-immersion stress in rats. Arzneimittelforschung 1986; 36: 1240-1244